Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dippoldiswalde – page 53

1 081 clinical trials in Dippoldiswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dippoldiswalde at a glance
1 081
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 081 trials in Dippoldiswalde

Open in trial search

Hepatic cirrhosis

Not recruiting

Study on Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis and Portal Hypertension

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Study of Pembrolizumab and Drug Combination for Patients with Advanced Esophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study Comparing Subcutaneous and Intravenous Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diabetic foot

Not recruiting

Study on AUP1602-C for Treating Non-Healing Diabetic Foot Ulcers in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AUP1602-C
  • Sponsor:Aurealis Oy

Type 1 diabetes mellitus+2

Not recruiting

Efficacy and Safety of Tirzepatide Versus Placebo in Adults with Type 1 Diabetes and Obesity or Overweight: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Conjunctivitis allergic+1

Not recruiting

Dose‑finding trial of a mannan‑conjugated Phleum pratense/Dactylis glomerata allergoid vaccine in patients with grass‑pollen allergic rhinitis or rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531
  • Sponsor:Kailera Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dippoldiswalde

What the registry says about research in the country

01 Respiratory Disease Research

Ongoing clinical investigations focus on respiratory syncytial virus (RSV) infections in older adults, specifically targeting those aged 60 and above. The research examines immune responses and safety profiles of preventive interventions.

  • Vaccine Development
  • Immune Response Analysis
  • Senior Population Health

This extension study builds upon previous research to evaluate the effectiveness of revaccination strategies and long-term immune protection against RSV infections in elderly populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.